Compare VRTX & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | BSX |
|---|---|---|
| Founded | 1989 | 1979 |
| Country | United States | United States |
| Employees | 6100 | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 137.8B |
| IPO Year | 1991 | 1992 |
| Metric | VRTX | BSX |
|---|---|---|
| Price | $457.11 | $96.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 17 |
| Target Price | ★ $494.64 | $125.88 |
| AVG Volume (30 Days) | 1.6M | ★ 10.8M |
| Earning Date | 02-09-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.68 |
| EPS | ★ 14.22 | 1.87 |
| Revenue | $11,723,300,000.00 | ★ $19,349,000,000.00 |
| Revenue This Year | $11.01 | $21.05 |
| Revenue Next Year | $8.74 | $11.43 |
| P/E Ratio | ★ $32.08 | $51.13 |
| Revenue Growth | 10.33 | ★ 21.61 |
| 52 Week Low | $362.50 | $85.98 |
| 52 Week High | $519.68 | $109.50 |
| Indicator | VRTX | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 49.71 |
| Support Level | $445.41 | $90.42 |
| Resistance Level | $459.05 | $97.27 |
| Average True Range (ATR) | 10.50 | 2.17 |
| MACD | 0.26 | 0.25 |
| Stochastic Oscillator | 83.14 | 67.66 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.